Financials data is unavailable for this security.
View more
Year on year Zhejiang Shengda Bio-Pharm Co Ltd had net income fall from a gain of 31.49m to a loss of 54.06m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 84.95% to 89.83%.
| Gross margin | 16.06% |
|---|---|
| Net profit margin | -3.83% |
| Operating margin | -3.90% |
| Return on assets | -1.71% |
|---|---|
| Return on equity | -2.45% |
| Return on investment | -2.02% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang Shengda Bio-Pharm Co Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 176.98m or 24.33% of revenues. In addition the company generated 64.42m in cash from operations while cash used for investing totalled 241.52m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 7.32 |
|---|---|
| Tangible book value per share | 5.92 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.96 |
|---|---|
| Quick ratio | 1.90 |
| Total debt/total equity | 0.2481 |
|---|---|
| Total debt/total capital | 0.1965 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -273.98%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.72% |
|---|---|
| Div growth rate (5 year) | -6.89% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -130.45 |
More ▼
